Articles tagged with Liver Damage
Research review finds handgrip strength is a reliable predictor of cirrhosis complications and outcomes, including malnutrition, muscle loss, cognitive impairment, hepatic encephalopathy, and mortality. Regular HGS assessments can inform timely personalized interventions to enhance patient quality of life.
Researchers have identified a gene signature indicative of hepatic ferroptosis using an iron overload-induced mouse model and validated it in human liver injury systems. The study highlights the role of ferroptosis in liver injuries and offers potential therapeutic targets.
Rifaximin's long-term efficacy in managing hepatic encephalopathy (HE) is supported by reduced ammonia levels and improved cognitive scores. Low-dose regimens show comparable efficacy to standard doses while offering cost-effectiveness.
Chronic liver diseases like MASLD and MASH affect 33% and 5% of adults worldwide, respectively. Experts propose doubling MASH diagnosis rate by 2027 to improve outcomes and reduce healthcare burdens. A paradigm shift towards preventive hepatology is key to addressing this growing public health threat.
Clinical trials for MASH cirrhosis have shown promising results, particularly with FGF21 analogues like efruxifermin and pegozafermin. The review emphasizes the need for effective interventions targeting advanced disease stages and highlights the importance of surrogate endpoints in accelerating approvals.
The new ShARP Center will investigate how PFAS affect liver health, and develop methods to detect and remove them from public water sources. Researchers will also study the link between PFAS exposure and rare cancers.
A VCU-led study suggests that semaglutide, a medication approved for weight loss and blood sugar control, may also reverse liver damage in patients with non-cirrhotic non-alcoholic steatohepatitis (MASH). Researchers found that nearly 90% of participants remained on the medication after 72 weeks without significant side effects.
Researchers successfully treated atherosclerosis and fatty liver disease using DT-109 in nonhuman primates, which has potential as a dual therapy for two common conditions. The compound reduced the formation of atherosclerotic plaques and stopped critical processes that lead to vascular calcification.
This study found that inhibiting cyclooxygenase-2 reduces liver ferroptosis and fibrosis by upregulating the Nrf2 signaling pathway. COX-2 inhibition also restored antioxidant defenses in hepatocytes, reducing oxidative stress and lipid peroxidation.
The study found that mitochondrial membrane potential (MMP) of CD8+ T cells is a significant predictor of bacterial infection (BI) and acute-on-chronic liver failure (ACLF) in cirrhotic patients. Low MMP levels were associated with increased risk of BI and ACLF.
A new editorial in Oncotarget discusses how artificial intelligence can improve liver imaging by recognizing when it might be wrong. The approach, called 'uncertainty quantification,' helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look.
Scientists discover blocking gasdermin D, a key inflammatory protein, improves liver health while damaging kidneys and brain in severe liver disease patients. The study's findings suggest that future therapies may need to target this pathway in a more nuanced way.
Researchers propose GLDH as a more liver-specific biomarker for detecting liver injury, offering greater specificity than current ALT and AST tests. The test performed similarly to ALT for detecting liver injury but was not impacted by associated muscle injury.
A single-center retrospective study analyzed clinical data, imaging, histopathological manifestations, genetic testing results, and treatment effects in 48 WD patients. The study found age at diagnosis, K-F ring presence, and higher immunoglobulin G levels were associated with cirrhosis risk factors.
Researchers have discovered a previously unknown mechanism of liver regeneration triggered by glutamate, which accelerates liver regeneration in minutes through changes in macrophage metabolism. Hepatocytes producing glutamine synthetase play a key role in this process.
A comprehensive study found that people with fatty liver disease have almost twice the mortality rate of the general population. The disease is caused by overweight or obesity and increases the risk of dying from various causes, including liver disease, cancer, cardiovascular disease, and infections.
Researchers found that females developed ascites later and were more susceptible to carbon tetrachloride toxicity than males. The study highlights the need for gender parity in preclinical studies and suggests that sex hormones may play a protective role against disease progression.
A new study published in Liver International found that a mother's high-fat diet during pregnancy can lead to liver stress and changes in the fetus's bile acid levels. This may be a key factor in the development of metabolic dysfunction-associated steatotic liver disease (MASLD) later in life.
Stellate cells, previously thought to only cause liver damage, have a surprising role in maintaining the liver's structure and function. The discovery could lead to a new therapeutic approach to treating metabolic liver disease, which affects hundreds of millions of people worldwide.
Excessive alcohol consumption causes severe digestive problems, including liver damage, stomach disorders, and increased cancer risk. Chronic alcohol use can lead to conditions like cirrhosis, pancreatitis, and colorectal cancer.
A recent study published in Science Advances reveals that high levels of ammonia kill liver cells by damaging mitochondria, leading to a vicious cycle of system breakdown. However, an existing drug called YAQ-005 can halt this damage and prevent liver cell death.
Ursodeoxycholic acid (UDCA) exhibits a broad range of hepatoprotective mechanisms, including antioxidant, anti-inflammatory, and anti-apoptotic properties, which may benefit various types of drug-induced liver injury. In hepatocellular DILI, UDCA reduces inflammation, alleviates ER stress, and protects against mitochondrial damage. In ...
SLC transporters contribute to the development of hepatic steatosis by regulating lipid metabolism, particularly with SLC2A2, GLUT4, and GLUT5. These proteins influence processes like de novo lipogenesis and insulin resistance in hepatocytes.
Researchers identified 19 metabolites and found that levels of certain compounds correlated with increased blood pressure, worse obstetric outcomes, and poorer end-organ function. The study expands scientific knowledge of preeclampsia and its mechanisms, paving the way for future therapeutic strategies.
A new classification system for SJS/TEN divides the disorder into five types based on causative factors and diagnostic algorithms. This typology aims to bring clarity to diagnosis and treatment by providing consistent criteria for identifying underlying causes.
A new trial will test whether taking HMB can improve patients' physical function and quality of life. The BOOST study aims to recruit 124 patients with cirrhosis and measure its effects on liver disease, mental wellbeing, and physical function over 24 weeks.
New research reveals that lipid-associated macrophages (LAMs) are crucial for liver repair, while Kupffer cells also adapt to take on a LAM-like phenotype. The Trem2 gene is essential for clearance of dying liver cells and promoting tissue repair.
A study found that patients with AMA/anti-sp100/anti-gp210 positivity and elevated liver enzymes can manifest conditions beyond primary biliary cholangitis. Etiological treatments improved or resolved cholestatic biochemistry in these patients, justifying their initiation over ursodeoxycholic acid therapy.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
A study found that chlorcyclizine, a decades-old allergy medication, could potentially treat erythropoietic protoporphyria (EPP), a condition creating extreme skin light sensitivity and toxic liver buildup. Chlorcyclizine may work by helping the liver clear toxic porphyrin buildup and reducing inflammation.
Researchers have discovered that AHCC suppresses liver fibrosis by inhibiting the activation of hepatic stellate cells through two channels. Early administration of AHCC may hold the key to preventing the onset of cirrhosis, a potentially fatal condition.
Researchers discovered a novel combination of plasma-based biomarkers that can predict liver fibrosis in Latino adolescents with obesity. The study found that dihydroxyacetone phosphate (DHAP) and alanine transaminase (ALT) were significantly associated with fibrosis, suggesting a potential low-cost, noninvasive screening tool.
The discovery of ferroptosis has renewed interest in non-apoptotic cell death mechanisms. While initially studied in cancer, ferroptosis is increasingly implicated in various diseases, including liver injury. However, the liver's robust antioxidant defenses question its widespread applicability.
A new study published in Lancet Gastroenterology and Hepatology found that a combined screening approach can detect liver damage in people with type 2 diabetes. The method involves elastography, an ultrasound-based technique, which was found to be willing to be adopted by most patients. Early detection of liver fibrosis is crucial, as ...
A new study finds that a blood test using phosphatidylethanol (PEth) can detect liver disease caused by excessive drinking, offering a more reliable alternative to self-reported measures. The test has shown strong correlation with Fibrosis 4, an indicator of liver risk, and could be included in routine blood tests.
A study found that ADAMTS13 regulates VWF expression and reduces hepatic platelet accumulation in PA-ILI patients and mice. Systemic administration of recombinant ADAMTS13 decreased platelet accumulation and mitigated liver necrosis.
A new research paper published in Oncotarget introduces an innovative AI tool combining CT scans and body composition data to predict severe liver problems in primary sclerosing cholangitis (PSC) patients. The model achieved impressive results, correctly identifying at-risk patients with 97% accuracy.
Researchers at Karolinska Institutet have identified two types of metabolic-associated fatty liver disease, a liver-specific type and a systemic type that affects other organs. The discovery could lead to improved diagnosis and treatment of this growing patient group, with potential benefits for cardiovascular health.
Researchers have created a new technique to rapidly assess paracetamol levels from saliva using Mass Spectrometry technology. The Paper-Arrow Mass Spectrometry (PA-MS) test is non-invasive, fast, and cost-effective, with the potential to improve patient care and outcomes.
A study found that cell ageing in one organ can spread to other organs, leading to multi-organ failure. Researchers identified a key protein that could be manipulated to prevent such failures.
High-mobility group box-1 (HMGB1) plays a critical role in liver disease pathogenesis, influencing both inflammatory and fibrotic pathways. Its roles in acute liver injury, chronic conditions, and liver cancer make it a valuable diagnostic and therapeutic target.
Experimental mouse models are crucial for studying liver fibrosis regression, with various models exhibiting reversible fibrosis after removal of causative agents or therapeutic interventions. However, challenges persist in replicating human disease progression and regression, highlighting the need for further refinement of these models.
Researchers from the University of Zurich have discovered a link between hepatitis E and kidney damage, finding that viral envelope-antibody complexes can accumulate in kidney filters and cause glomerulonephritis. The study uses tissue samples from patients to understand the disease mechanism.
This study investigates the role of GPX4 methylation in ferroptosis during hepatic ischemia-reperfusion injury. Ferroptosis is observed in oxygen and glucose deprivation, characterized by decreased cellular viability and increased lipid peroxidation.
Researchers investigate how liver necroptosis triggers inflammation in both organs, leading to cognitive impairment. Studying aging mouse models, they found that liver necroptosis causes systemic inflammation affecting brain function.
Researchers found inhibiting ACMSD increases NAD+ levels, reducing inflammation and fibrosis in mouse models of MASLD/MASH. Boosting NAD+ production could protect against severe liver damage and cirrhosis.
The TIPS procedure improves renal function in patients with portal hypertension, particularly those with refractory ascites. However, the benefits of TIPS for Hepatorenal Syndrome (HRS) and Hepatopulmonary Syndrome (HPS) are limited due to insufficient data.
Researchers identified CYP1B1 as a biomarker for HSC activation and liver fibrosis in patients and mice. Inhibition of CYP1B1 led to the accumulation of trehalose, which has anti-fibrotic activity, protecting mice from liver fibrosis.
Researchers developed a multi-variable model called Hear-MHE that analyzes speech patterns to identify symptoms of minimal hepatic encephalopathy. The test shows promise in predicting overt hepatic encephalopathy and could lead to earlier diagnosis and improved treatment.
Cholestasis leads to mitochondrial dysfunction, ER stress, inflammation, and autophagy impairment. Novel therapeutic agents modulate mitochondrial and bile acid metabolism pathways to improve liver function.
A WVU biologist is studying how genes establish animal body plans and contribute to regenerative abilities. He has identified Hox genes as key players in planarian regeneration, suggesting their functions may differ in highly regenerative versus poorly regenerative organisms.
A study from Michigan Medicine researchers found that over 15 million adult Americans regularly consume herbal and dietary supplements containing potentially toxic liver ingredients. The largest proportion of users took turmeric or green tea supplements, while others used garcinia cambogia for weight loss.
A new study sheds light on fatty liver disease MASH's pathology, revealing T cell activation and growth in response to poor diet. The research holds promise for developing a biomarker test to track disease progression before it's at a late stage.
A recent UNIGE study highlights the risks of high-protein diets, also known as Paleolithic diets, which can lead to severe neurological disorders. Excess protein increases ammonium production, overwhelming the liver and potentially causing coma in severe cases.
Alcoholic liver disease is a major public health concern in China, influenced by cultural factors and high alcohol consumption. The disease's increasing prevalence and severe complications highlight the need for comprehensive strategies to manage and prevent ALD.
Significant progress has been made in understanding and managing cholestatic liver diseases, with emerging therapies like OCA, fibrates, and budesonide. Multidisciplinary approaches involving hepatologists, gastroenterologists, and primary care physicians are crucial for improving patient outcomes.
A team of researchers has discovered a mechanism by which the liver's immune cells are suppressed in chronic hepatitis B, leading to organ damage. The 'sleep timer' function allows immune cells to weaken their activity over time, preventing them from proliferating excessively and causing further damage.
A new study led by researchers from the University of Pennsylvania School of Medicine developed a novel approach to assess medication-related liver injury. By analyzing real-world health care data, they found that some medications' levels of danger to the liver are being misclassified.
Research found that RAMP1 protects liver cells from damage caused by ischemia-reperfusion injury. The protein inhibited the ERK/YAP pathway, leading to reduced cell death and inflammation. This study highlights RAMP1's potential as a therapeutic target for treating this condition.
Studies found a negative relationship between HBV replication and liver inflammation in HBeAg-positive patients with high viral DNA levels, which shifted to positive relationships for those with low DNA levels or HBeAg-negative status. This interaction suggests a complex relationship between viral replication and liver damage progression.